Expert Insights into the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic Leukemia - Episode 6

Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion

, ,

Dr. Roloff and colleagues offer expert opinion on optimizing treatment sequences for patients with relapsed or refractory ALL who have received two or more prior lines of therapy and the disease and patient factors that inform their treatment plans.

EP. 1: Faculty Introductions
EP. 2: Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL
EP. 3: Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL
EP. 4: Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical Trial
EP. 5: Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease
Now Viewing
EP. 6: Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion
EP. 7: Outcomes of the Retrospective, Multicenter ROCCA Analysis (Real-World Outcomes Collaborative of CAR-T in Adult ALL)
EP. 8: Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy
EP. 9: Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL
EP. 10: Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia

Related Content:

Expert Insights into the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic LeukemiaHematologic Oncology
Dr Cherng on Considerations for the Use of Bispecific Antibodies in DLBCL
Dr Daver on the Initial Safety of DSP-5336 in Relapsed/Refractory Acute Leukemia
DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)